Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2004

View Archived Issues

ON-1910Na effective against human liver cancer in vivo

Novel iNOS inhibitor against inflammation

KS-119, a potential hypoxic cell cytotoxin

Palmitoyl-CoA oxidation inhibitor analogues for inducing metabolic shift

Novel camptothecin derivatives with enhanced stability and antitumor activity

Access' AP-5346 shows greater Pt delivery to tumor DNA than oxaliplatin

Phytobiotech changes name to Avance Pharma

Review of phase II Propofol IDD-D results completed

Financing at Favrille supports phase II and phase III trials

Targeted Genetics and Elan conclude Emerald Gene Systems joint venture

Eisai to promote Imurek in Germany

Inflazyme to acquire Adprotech

KV Pharmaceutical and Arrow sign marketing deal for Gynazole-1

Factor 5A1 induces apoptosis in lung cancer mice study

INGN-241 enters phase II trial in metastatic melanoma

European approval sought for candesartan cilexetil for chronic heart failure

Novartis to license calcitonin technology from Unigene

Extina NDA accepted for filing

Genta presents new data on the antitumor effects of oblimersen sodium and gallium nitrate

Micellar paclitaxel improves symptoms of severe psoriasis

CXCR2 receptor antagonists claimed in AstraZeneca patent

Novel modulators of chemokine CCR5 receptor activity identified by AstraZeneca

Bayer patents PDE9 inhibitors for improving learning, memory and concentration

Benzoyl piperidine compounds for CNS disorders

GSK claims new potent and selective COX-2 inhibitors for pain, inflammation, etc.

Dual serotonin reuptake inhibitors/alpha2-adrenoceptor antagonists emerge from Janssen research

Topical tacrolimus reported effective in a mild case of vesicular pemphigoid

Novel optimized antimalarial artemisinin analogues

Melanin-concentrating hormone receptor antagonist against obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...